Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, April 17, 2017

Firefighter with Relapsing MS on Ocrevus: ‘I Have Really Good Days and I Have Bad Days’

Click here to receive MS news via e-mail

Texas firefighter Wayne Donovan is among the estimated 250,000 to 350,000 Americans with multiple sclerosis (MS). He enrolled in a clinical trial testing Ocrevus (ocrelizumab), which the  U.S. Food and Drug Administration recently approved as the first therapy for both relapsing and primary progressive forms of MS.
Donovan was diagnosed in 2011 at the age of 39, after he started feeling numbness in his hand and foot and saw a orthopedist, thinking he might have pinched a nerve. The orthopedist, however, recognized that it could be something more serious and referred him to neurologist Dr. Edward Fox at Central Texas Neurology Consultants in suburban Austin.
Fox diagnosed Donovan with relapsing MS — an unpredictable form of the disease.
Texas firefighter and MS patient Wayne Donovan. (Photo credit: Ocrevus)
“By the time I saw Dr. Fox, about three-quarters of my body was either numb or tingling, or had pins and needles,” Donovan said in a news release. “As a firefighter, I have to be strong and present in tough situation. I didn’t know what this meant for me and my family.”
The ultimate cause of MS is damage to myelin, nerve fibers and neurons in the brain and spinal cord, which together make up the central nervous system, causing inflammation and other debilitating symptoms. Relapsing MS is characterized by episodes of new or worsening signs or relapses, followed by periods of recovery.
Ocrevus targets immune B-cells that express a protein called CD20 on their surface, giving the drug an immunosuppressive function. The medication, developed by Genentech — a unit of the Roche Group — aims to reduce the immune system’s attacks on myelinated neurons, the main trigger of the disease.
Fox knew about a clinical trial that was investigating Ocrevus and suggested that Donovan enroll. After considering the pros and cons, Donovan enrolled and started receiving Ocrevus soon after. In the trial, the drug was administered every six months as an intravenous infusion.

MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

No comments: